Walleye Capital LLC Invests $461,000 in MaxCyte, Inc. (NASDAQ:MXCT)

Walleye Capital LLC purchased a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 110,891 shares of the company's stock, valued at approximately $461,000. Walleye Capital LLC owned approximately 0.10% of MaxCyte as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Prudential Financial Inc. bought a new position in shares of MaxCyte in the fourth quarter valued at approximately $65,000. Catalyst Funds Management Pty Ltd acquired a new position in MaxCyte in the 4th quarter valued at $74,000. China Universal Asset Management Co. Ltd. raised its holdings in MaxCyte by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company's stock worth $93,000 after acquiring an additional 2,154 shares during the period. EntryPoint Capital LLC acquired a new position in MaxCyte during the 4th quarter worth $185,000. Finally, SG Americas Securities LLC boosted its holdings in MaxCyte by 25.9% during the fourth quarter. SG Americas Securities LLC now owns 47,805 shares of the company's stock valued at $199,000 after acquiring an additional 9,836 shares during the period. Institutional investors and hedge funds own 68.81% of the company's stock.

Wall Street Analysts Forecast Growth

MXCT has been the subject of several recent analyst reports. Stifel Nicolaus decreased their target price on MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, March 12th. BTIG Research set a $6.00 target price on shares of MaxCyte and gave the stock a "buy" rating in a research report on Wednesday, March 12th.

MaxCyte Trading Down 0.9 %

MXCT stock traded down $0.03 during trading on Tuesday, reaching $2.90. 56,155 shares of the stock were exchanged, compared to its average volume of 533,768. The stock has a 50 day simple moving average of $3.00 and a 200-day simple moving average of $3.69. The company has a market capitalization of $307.78 million, a P/E ratio of -8.51 and a beta of 1.39. MaxCyte, Inc. has a twelve month low of $2.21 and a twelve month high of $5.26.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.